期刊
JOURNAL OF PATHOLOGY
卷 244, 期 5, 页码 565-577出版社
WILEY
DOI: 10.1002/path.5038
关键词
lung cancer; targeted therapy; precision medicine; EGFR; ALK; PD-1; PD-L1
资金
- Damon Runyon Clinical Investigator Award
- LUNGevity Career Development Award
- V Foundation Scholar-in-Training Award
- AACR-Genentech Career Development Award
- Vanderbilt Ingram Cancer Center Young Ambassadors Award
- National Institutes of Health (NIH)
- National Cancer Institute (NCI) [R01CA121210, P01CA129243, U10CA180864, P30CA068485-13S5]
- [F30CA206339]
- NATIONAL CANCER INSTITUTE [U10CA180864, P30CA068485, P01CA129243, R01CA121210] Funding Source: NIH RePORTER
Although histological subtype still underlies tumour classification and treatment, the recognition that lung cancer is, largely, a genetic disease has prompted a push to reconfigure cancer taxonomies according to molecular criteria. In this review, we discuss established (e.g. EGFR, ALK, ROS1, and programmed cell death 1/programmed death-ligand 1), emerging (e.g. MET, RET, and NTRK) and elusive (e.g. TP53, KRAS, and MYC) molecular targets in the treatment of lung cancer. We synthesize a large and rapidly growing body of literature regarding the discovery and therapeutic inhibition of these targets in lung cancer. Copyright (C) 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据